Psilocybin for treating substance use disorders?

References

• Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study 2010. Lancet. 2013;382(9904):1564–1574.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Griffin ML, Mirin SM. Drug abuse as self-medication for depression: an empirical study. Am J Drug Alcohol Abuse. 1992;18(2):121–129.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Maisto SA, Pollock NK, et al. Rapid relapse generally follows treatment for substance use disorders among adolescents. Addict Behav. 2003;28(2):381–386.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, fifth edition. 5th ed.
   Google Scholar
• Volkow ND, Li T-K. Science and society - Drug addiction: the neurobiology of behaviour gone awry. Nat Rev Neurosci. 2004;5(12):963–970.
   PubMed Web of Science ®Google Scholar
• Dailly E, Chenu F, Renard CE, et al. Dopamine, depression and antidepressants. Fundam Clin Pharmacol. 2004;18(6):601–607.
   PubMed Web of Science ®Google Scholar
• Swendsen JD, Merikangas KR. The comorbidity of depression and substance use disorders. Clin Psychol Rev. 2000;20(2):173–189.
   PubMed Web of Science ®Google Scholar
• Howell LL, Cunningham KA. Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev. 2015;67(1):176–197.
   PubMed Web of Science ®Google Scholar
• Cools R, Roberts AC, Robbins TW. Serotoninergic regulation of emotional and behavioural control processes. Trends Cogn Sci. 2008;12(1):31–40.
   PubMed Web of Science ®Google Scholar
• Müller CP, Homberg JR. The role of serotonin in drug use and addiction. Behav Brain Res. 2015;277:146–192.
   PubMed Web of Science ®Google Scholar
• You I-J, Wright SR, Garcia-Garcia AL, et al. 5-HT1A autoreceptors in the dorsal raphe nucleus convey vulnerability to compulsive cocaine seeking. Neuropsychopharmacology. 2016;41(5):1210–1222.
   PubMed Web of Science ®Google Scholar
• Koob GF. The dark side of emotion: the addiction perspective. Eur J Pharmacol. 2015;753:73–87.
   PubMed Web of Science ®Google Scholar
• Goeders NE, Guerin GF. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats. Brain Res. 1996;722(1–2):145–152.
   PubMed Web of Science ®Google Scholar
• Koob GF. Brain stress systems in the amygdala and addiction. Brain Res. 2009;1293:61–75.
   PubMed Web of Science ®Google Scholar
• Hata T, Chen J, Ebihara K, et al. Intra-ventral tegmental area or intracerebroventricular orexin-A increases the intra-cranial self-stimulation threshold via activation of the corticotropin-releasing factor system in rats. Eur J Neurosci. 2011;34(5):816–826.
   PubMed Web of Science ®Google Scholar
• Commons KG, Connolley KR, Valentino RJ. A neurochemically distinct dorsal raphe-limbic circuit with a potential role in affective disorders. Neuropsychopharmacology. 2003;28(2):206–215.
   PubMed Web of Science ®Google Scholar
• van der Doelen RHA, Deschamps W, D’Annibale C, et al. Early life adversity and serotonin transporter gene variation interact at the level of the adrenal gland to affect the adult hypothalamo-pituitary-adrenal axis. Transl Psychiatry. 2014;4:e409.
   PubMed Web of Science ®Google Scholar
• Verheij MMM, Karel P, Cools AR, et al. Reduced cocaine-induced serotonin, but not dopamine and noradrenaline, release in rats with a genetic deletion of serotonin transporters. Eur Neuropsychopharmacol. 2014;24(11):1850–1854.
   PubMed Web of Science ®Google Scholar
• Homberg JR, De Boer SF, Raasø HS, et al. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology (Berl). 2008;200(3):367–380.
   PubMed Web of Science ®Google Scholar
• Nonkes LJP, Van Bussel IPG, Verheij MMM, et al. The interplay between brain 5-hydroxytryptamine levels and cocaine addiction. Behav Pharmacol. 2011;22(8):723–738.
   PubMed Web of Science ®Google Scholar
• Maclean JR, Macdonald DC, Byrne UP, et al. The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Q J Stud Alcohol. 1961;22:34–45.
   PubMedGoogle Scholar
• Krebs TS, Johansen P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994–1002.
   PubMed Web of Science ®Google Scholar
• Smart RG, Storm T. The efficacy of LSD in the treatment of alcoholism. Q J Stud Alcohol. 1964;25:333–338.
   PubMedGoogle Scholar
• Costello CG. An evaluation of aversion and LSD therapy in the treatment of alcoholism. Can Psychiatr Assoc J. 1969;14(1):31–42.
   PubMedGoogle Scholar
• Johnson FG. LSD in the treatment of alcoholism. Am J Psychiatry. 1969;126(4):481–487.
   PubMed Web of Science ®Google Scholar
• Smart RG, Storm T, Baker EF, et al. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966;27(3):469–482.
   PubMedGoogle Scholar
• Denson R, Sydiaha D. A controlled study of LSD treatment in alcoholism and neurosis. Br J Psychiatry. 1970;116(533):443–445.
   PubMed Web of Science ®Google Scholar
• MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011;25(11):1453–1461.
   PubMed Web of Science ®Google Scholar
• Gallimore AR.Restructuring consciousness the psychedelic state in light of integrated information theory.Front Hum Neurosci.2015;9:346.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards W, Johnson M, et al. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22(6):621–632.
   PubMed Web of Science ®Google Scholar
• Doblin R. Pahnke good-Friday experiment - a long-term follow-up and methodological critique. J Transpersonal Psychol. 1991;23(1):1–28.
   Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78.
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Forcehimes AA, Pommy JA, et al. A pilot study of psilocybin-assisted treatment for alcohol dependence: acute effects and short-term alcohol use, self-efficacy, and craving. Alcoholism-Clinical Exp Res. 2014;38:155a–155a.
   Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28:983–992.
   PubMed Web of Science ®Google Scholar
• Burdick BV, Adinoff B. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment. Am J Drug Alcohol Abuse. 2013;39(5):291–297.
   PubMed Web of Science ®Google Scholar
• Hendricks PS, Clark CB, Johnson MW, et al. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol. 2014;28(1):62–66.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006;187(3):268–292. discussion 284-92
   PubMed Web of Science ®Google Scholar
• Laussmann T, Meier-Giebing S. Forensic analysis of hallucinogenic mushrooms and khat (Catha edulis FORSK) using cation-exchange liquid chromatography. Forensic Sci Int. 2010;195(1–3):160–164.
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, et al. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2006;67(11):1735–1740.
   PubMed Web of Science ®Google Scholar
• Tylš F, Páleníček T, Horáček J. Psilocybin – summary of knowledge and new perspectives. Eur Neuropsychopharmacol. 2014;24(3):342–356.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642–651.
   PubMed Web of Science ®Google Scholar
• Horita A, Weber LJ. The enzymic dephosphorylation and oxidation of psilocybin and psilocin by mammalian tissue homogenates. Biochem Pharmacol. 1961;7:47–54.
   PubMed Web of Science ®Google Scholar
• Grieshaber AF, Moore KA, Levine B. The detection of psilocin in human urine. J Forensic Sci. 2001;46(3):627–630.
   PubMed Web of Science ®Google Scholar
• Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101(2):131–181.
   PubMed Web of Science ®Google Scholar
• Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357–364.
   PubMed Web of Science ®Google Scholar
• Cerletti A. Etude pharmacologique de la psilocybine. In: Heim R, Wasson RG, Editor. Editions du Museum National d’Historie Naturalle. 1st ed. Paris: Editions du Museum National d’Historie Naturalle; 1958. p. 268–271.
   Google Scholar
• Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620.
   PubMed Web of Science ®Google Scholar
• Gerault A, Picart D. Fatal poisoning after a group of people voluntarily consumed hallucinogenic mushrooms. Bull Soc Mycol Fr. 1996;112(1):1–14.
   Google Scholar
• Lim TH, Wasywich CA, Ruygrok PN. A fatal case of ‘magic mushroom’ ingestion in a heart transplant recipient. Intern Med J. 2012;42(11):1268–1269.
   PubMed Web of Science ®Google Scholar
• Klock JC, Boerner U, Becker CE. Coma, hyperthermia, and bleeding associated with massive LSD overdose, a report of eight cases. Clin Toxicol. 1975;8(2):191–203.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci USA. 2012;109(6):2138–2143.
   PubMed Web of Science ®Google Scholar
• Stebelska K. Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities. Ther Drug Monit. 2013;35(4):420–442.
   PubMed Web of Science ®Google Scholar
• McKenna DJ, Repke DB, Lo L, et al. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology. 1990;29(3):193–198.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–3902.
   PubMed Web of Science ®Google Scholar
• Fiorella D, Rabin RA, Winter JC. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs .1. Antagonist correlation-analysis. Psychopharmacology (Berl). 1995;121(3):347–356.
   PubMed Web of Science ®Google Scholar
• Glennon RA, Titeler M, Mckenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35(25):2505–2511.
   PubMed Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology. 2011;61(3):364–381.
   PubMed Web of Science ®Google Scholar
• Strassman RJ. Human psychopharmacology of N,N-dimethyltryptamine. Behav Brain Res. 1996;73(1–2):121–124.
   PubMed Web of Science ®Google Scholar
• Hall H, Farde L, Halldin C, et al. Autoradiographic localization of 5-HT2A receptors in the human brain using (LH)-H-3]M100907 and [C-11]M100907. Synapse. 2000;38(4):421–431.
   PubMed Web of Science ®Google Scholar
• Davidson MC, Amso D, Anderson LC, et al. Development of cognitive control and executive functions from 4 to 13 years: evidence from manipulations of memory, inhibition, and task switching. Neuropsychologia. 2006;44(11):2037–2078.
   PubMed Web of Science ®Google Scholar
• Bombardi C. Neuronal localization of the 5-HT2 receptor family in the amygdaloid complex. Front Pharmacol. 2014;5:68.
   PubMed Web of Science ®Google Scholar
• Bocchio M, Fucsina G, Oikonomidis L, et al. Increased serotonin transporter expression reduces fear and recruitment of parvalbumin interneurons of the amygdala. Neuropsychopharmacology. 2015;40(13):3015–3026.
   PubMed Web of Science ®Google Scholar
• Everitt BJ, Parkinson JA, Olmstead MC, et al. Associative processes in addiction and reward - The role of amygdala-ventral striatal subsystems. Ann N Y Acad Sci. 1999;877:412–438.
   PubMed Web of Science ®Google Scholar
• Franklin JM, Mathew M, Carrasco GA. Cannabinoid-induced upregulation of serotonin 2A receptors in the hypothalamic paraventricular nucleus and anxiety-like behaviors in rats. Neurosci Lett. 2013;548:165–169.
   PubMed Web of Science ®Google Scholar
• Lee TT-Y, Redila VA, Hill MN, et al. Receptor mediated neuronal activation within the paraventricular nucleus of the hypothalamus is desensitized following prolonged glucocorticoid treatment. Eur J Pharmacol. 2009;602(1):54–57.
   PubMed Web of Science ®Google Scholar
• Carrasco GA, Van de Kar LD, Sullivan NR, et al. Cocaine-mediated supersensitivity of 5-HT2A receptors in hypothalamic paraventricular nucleus is a withdrawal-induced phenomenon. Neuroscience. 2006;143(1):7–13.
   PubMed Web of Science ®Google Scholar
• Sotelo C, Cholley B, El Mestikawy S, et al. Direct Immunohistochemical evidence of the existence of 5-HT1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur J Neurosci. 1990;2(12):1144–1154.
   PubMed Web of Science ®Google Scholar
• Rao U. Comorbidity between depressive and addictive disorders in adolescents: role of stress and HPA activity. US Psyc. 2010;3:39–43.
   PubMedGoogle Scholar
• Asan E, Steinke M, Lesch K-P. Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety. Histochem Cell Biol. 2013;139(6):785–813.
   PubMed Web of Science ®Google Scholar
• Zhang GL, Stackman RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol. 2015;6:225.
   Web of Science ®Google Scholar
• Ogren SO, Eriksson TM, Elvander-Tottie E, et al. The role of 5-HT1A receptors in learning and memory. Behav Brain Res. 2008;195(1):54–77.
   PubMed Web of Science ®Google Scholar
• López JF, Chalmers DT, Little KY, et al. Regulation of serotonin(1A), glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry. 1998;43(8):547–573.
   PubMed Web of Science ®Google Scholar
• Yates M, Leake A, Candy JM, et al. 5HT2 receptor changes in major depression. Biol Psychiatry. 1990;27(5):489–496.
   PubMed Web of Science ®Google Scholar
• Schreiber R, De Vry J. 5-HT1A receptor ligands in animal models of anxiety, impulsivity and depression: multiple mechanisms of action? Prog Neuropsychopharmacol Biol Psychiatry. 1993;17(1):87–104.
   PubMed Web of Science ®Google Scholar
• Berendsen HH. Interactions between 5-hydroxytryptamine receptor subtypes: is a disturbed receptor balance contributing to the symptomatology of depression in humans? Pharmacol Ther. 1995;66(1):17–37.
   PubMed Web of Science ®Google Scholar
• Kraehenmann R, Preller KH, Scheidegger M, et al. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry. 2014;78(8):572–581.
   PubMed Web of Science ®Google Scholar
• Childress AR, Mozley PD, McElgin W, et al. Limbic activation during cue-induced cocaine craving. Am J Psychiatry. 1999;156(1):11–18.
   PubMed Web of Science ®Google Scholar
• Ouellet-Morin I, Odgers CL, Danese A, et al. Blunted cortisol responses to stress signal social and behavioral problems among maltreated/bullied 12-year-old children. Biol Psychiatry. 2011;70(11):1016–1023.
   PubMed Web of Science ®Google Scholar
• Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom Med. 2011;73(2):114–126.
   PubMed Web of Science ®Google Scholar
• Schepis TS, Rao U, Yadav H, et al. The limbic-hypothalamic-pituitary-adrenal axis and the development of alcohol use disorders in youth. Alcoholism-Clin Exp Res. 2011;35(4):595–605.
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Ritchie JC, et al. The 5-hydroxytryptamine2 agonist, (+/-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. 1. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat-brain. J Pharmacol Exp Ther. 1991;256(2):787–794.
   PubMed Web of Science ®Google Scholar
• Hasler F, Grimberg U, Benz MA, et al. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004;172(2):145–156.
   PubMed Web of Science ®Google Scholar
• Lupien SJ, Wilkinson CW, Brière S, et al. The modulatory effects of corticosteroids on cognition: studies in young human populations. Psychoneuroendocrinology. 2002;27(3):401–416.
   PubMed Web of Science ®Google Scholar
• Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–238.
   PubMed Web of Science ®Google Scholar
• Wu JH, Zhang S, Li W, et al. Cortisol awakening response predicts intrinsic functional connectivity of the medial prefrontal cortex in the afternoon of the same day. Neuroimage. 2015;122:158–165.
   PubMed Web of Science ®Google Scholar
• Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci. 2011;15(10):483–506.
   PubMed Web of Science ®Google Scholar
• Sutherland MT, McHugh MJ, Pariyadath V, et al. Resting state functional connectivity in addiction: lessons learned and a road ahead. Neuroimage. 2012;62(4):2281–2295.
   PubMed Web of Science ®Google Scholar
• Kraehenmann R, Schmidt A, Friston K, et al. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin. 2016;11:53–60.
   PubMed Web of Science ®Google Scholar
• Kometer M, Schmidt A, Bachmann R, et al. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012;72(11):898–906.
   PubMed Web of Science ®Google Scholar
• Hermans EJ, Battaglia FP, Atsak P, et al. How the amygdala affects emotional memory by altering brain network properties. Neurobiol Learn Mem. 2014;112:2–16.
   PubMed Web of Science ®Google Scholar
• King AR, Martin IL, Melville KA. Reversal learning enhanced by lysergic acid diethylamide (LSD): concomitant rise in brain 5-hydroxytryptamine levels. Brit J Pharmacol. 1974;52(3):419–426.
   PubMed Web of Science ®Google Scholar
• Roberts MHT, Bradley PB. Studies on the effects of drugs on performance of a delayed discrimination. Physiol Behav. 1967;2(4):389–397.
   Web of Science ®Google Scholar
• Boulougouris V, Glennon JC, Robbins TW. Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology. 2008;33(8):2007–2019.
   PubMed Web of Science ®Google Scholar
• Furr A, Lapiz-Bluhm MD, Morilak DA. 5-HT2A receptors in the orbitofrontal cortex facilitate reversal learning and contribute to the beneficial cognitive effects of chronic citalopram treatment in rats. Int J Neuropsychopharmacol. 2012;15(9):1295–1305.
   PubMed Web of Science ®Google Scholar
• Depoortere R, Auclair AL, Bardin L, et al. F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol. 2010;20(9):641–654.
   PubMed Web of Science ®Google Scholar
• Terracciano A, Löckenhoff CE, Crum RM, et al. Five-factor model personality profiles of drug users. Bmc Psychiatry. 2008;8:22.
   PubMed Web of Science ®Google Scholar
• Leber AB, Turk-Browne NB, Chun MM. Neural predictors of moment-to-moment fluctuations in cognitive flexibility. Proc Natl Acad Sci USA. 2008;105(36):13592–13597.
   PubMed Web of Science ®Google Scholar
• Zinberg N. Drug, set, and setting: the basis for controlled intoxicant use. New Haven (CT): Yale University Press; 1984. p. x–xi.
   Google Scholar
• Studerus E, Gamma A, Kometer M, et al. Prediction of psilocybin response in healthy volunteers. PLoS One. 2012;7(2):e30800.
   PubMed Web of Science ®Google Scholar
• Cohen S. Lysergic-acid diethylamide - side-effects and complications. J Nervous Ment Dis. 1960;130(1):30–40.
   PubMed Web of Science ®Google Scholar
• Roth BL, Berry SA, Kroeze WK, et al. Serotonin 5-HT2A receptors: molecular biology and mechanisms of regulation. Crit Rev Neurobiol. 1998;12(4):319–338.
   PubMedGoogle Scholar
• Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol. 2004;15(2):149–157.
   PubMed Web of Science ®Google Scholar